Linshuichonetes gen. nov., a new rugosochonetid (Brachiopoda) genus from the Liangshan Formation (Early Permian) in Sichuan, China, and its ecology

A new genus and species, Linshuichonetes elfinis, belonging to the Rugosochonetidae, is described from the Early Permian (Late Artinskian or early Kungurian) Liangshan Formation of the Yangtze block. The new genus is defined externally by the presence of fine, but delayed, capillation and a weak or absent median sulcus and fold and by the presence of a distinct posteromedian sinus on the ventral umbo; and internally by a lack of median, lateral and accessory septa in the dorsal interior; absence of vascular trunks in the ventral interior and the presence of distinct radiating rows of papillae in the interior of both valves, particularly an unusual clustered arrangement of papillae on the posteromedian portion of the dorsal interior. The local environment during the deposition of the Liangshan Formation appears to have been a restricted tidal flat or lagoon which experienced frequent sealevel fluctuations associated with the onset of the Yanghsingian transgression. The new species, L. elfinis, appears to have several morphological adaptations enabling successful exploitation of this environment. It was typically a very small and thin-valved species with a high surface area to volume ratio, an advantage in an oxygen restricted environment. The small size and numerous body spinules would have aided individuals to remain suspended at the top of the fine, soft substrate. It also dominated the brachiopod assemblage in the Liangshan Formation, comprising up to 94%of specimens within a bed. These factors indicate that the new species appears to be an opportunistic species.

Identification of a putative egg-laying hormone in neural and ovarian tissues of the black tiger shrimp, Penaeus monodon, using immunocytochemistry

The existence of an egg-laying hormone (ELH) was identified for the first time in the black tiger shrimp, Penaeus monodon, by means of immunoenzyme and immunofluorescence techniques. This was achieved using a polyclonal antibody produced against expressed recombinant ELH of the female Australian blacklip abalone, Haliotis rubra. The shrimp ELH reactive material was found to be localised within female neurosecretory tissues and the secretory tissue of the antennal gland, but was not identified in the X-organ sinus gland within the eyestalk. It was also present in the ovary, where the amount of ELH present was observed to be greatest in the period prior to spawning. These findings implied that the induction of P. monodon spawning might be involved with humoral regulation relating to ELH expression.

Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial

Amiodarone is an effective medication in preventing atrial fibrillation (AF), but it interferes with the metabolism of warfarin.

Individualized arrhythmia detection with ECG signals from wearable devices

Low cost pervasive electrocardiogram (ECG) monitors is changing how sinus arrhythmia are diagnosed among patients with mild symptoms. With the large amount of data generated from long-term monitoring, come new data science and analytical challenges. Although traditional rule-based detection algorithms still work on relatively short clinical quality ECG, they are not optimal for pervasive signals collected from wearable devices - they don't adapt to individual difference and assume accurate identification of ECG fiducial points. To overcome these short-comings of the rule-based methods, this paper introduces an arrhythmia detection approach for low quality pervasive ECG signals. To achieve the robustness needed, two techniques were applied. First, a set of ECG features with minimal reliance on fiducial point identification were selected. Next, the features were normalized using robust statistics to factors out baseline individual differences and clinically irrelevant temporal drift that is common in pervasive ECG. The proposed method was evaluated using pervasive ECG signals we collected, in combination with clinician validated ECG signals from Physiobank. Empirical evaluation confirms accuracy improvements of the proposed approach over the traditional clinical rules.

Fructose-1, 6-diphosphate (FDP) as a novel antidote for yellow oleander-induced cardiac toxicity: a randomized controlled double blind study

BACKGROUND: Cardiac toxicity due to ingestion of oleander plant seeds in Sri Lanka and some other South Asian countries is very common. At present symptomatic oleander seed poisoning carries a mortality of 10% in Sri Lanka and treatment of yellow oleander poisoning is limited to gastric decontamination and atropine administration. The only proven effective antidote is digoxin antibodies but these are not available for routine use because of the high cost. The main objective of this study is to investigate the effectiveness of a new and inexpensive antidote for patients with life threatening arrhythmias due oleander poisoning. METHOD/DESIGN: We set up a randomised double blind clinical trial to assess the effectiveness of Fructose 1, 6 diphosphate (FDP) in acute yellow oleander poisoning patients admitted to the adult medical wards of a tertiary hospital in Sri Lanka. Patients will be initially resuscitated following the national guidelines and eligible patients will be randomised to receive either FDP or an equal amount of normal saline. The primary outcome measure for this study is the sustained reversion to sinus rhythm with a heart rate greater than 50/min within 2 hours of completion of FDP/placebo bolus. Secondary outcomes include death, reversal of hyperkalaemia on the 6, 12, 18 and 24 hour samples and maintenance of sinus rhythm on the holter monitor. Analysis will be on intention-to-treat. DISCUSSION: This trial will provide information on the effectiveness of FDP in yellow oleander poisoning. If FDP is effective in cardiac glycoside toxicity, it would provide substantial benefit to the patients in rural Asia. The drug is inexpensive and thus could be made available at primary care hospitals if proven to be effective. TRIAL REGISTRATION: Current Controlled trial ISRCTN71018309.

An international observational prospective survey assessing the control of atrial fibrillation in Asia-Pacific: results of the record-AFAP registry

A prospective 1-year observational survey was designed to assess the management and control of atrial fibrillation (AF) in eight countries within the Asia-Pacific region. Patients (N = 2,604) with recently diagnosed AF or a history of AF ≤1 year were included. Clinicians chose the treatment strategy (rhythm or rate control) according to their standard practice and medical discretion. The primary endpoint was therapeutic success. At baseline, rhythm- and rate-control strategies were applied to 35.7% and 64.3% of patients, respectively. At 12 months, therapeutic success was 43.2% overall. Being assigned to rhythm-control strategy at baseline was associated with a higher therapeutic success (46.5% vs 41.4%; P = 0.0214) and a lower incidence of clinical outcomes (10.4% vs 17.1% P < 0.0001). Patients assigned to rate-control strategies at baseline had higher cardiovascular morbidities (history of heart failure or valvular heart disease). Cardiovascular outcomes may be less dependent on the choice of treatment strategy than cardiovascular comorbidities.